Report cover image

Top 10 Strategic Imperatives in the Life Sciences Industry, 2025

Publisher Frost & Sullivan
Published Feb 19, 2025
SKU # MC19648640

Description

Owing to constant developments and challenges in the life sciences industry, stakeholders must continue to be adaptable, innovative, and competitive to thrive. Industry leaders must reconsider their strategic positions annually by understanding the main forces behind the transformation, including potential, challenges, and drivers.

This analysis explores the strategic imperatives shaping and transforming the life sciences industry.

They are as follows:
SaaS evolution provides adaptive intelligence for laboratories
CDMOs augment competencies in new modalities, and digital transformation delivers end-to-end partnerships
Expanding direct-to-consumer (DTC) genetic testing beyond ancestry testing to multi-pathogenic STIs
Uncertainty about trade wars disrupts pharmaceutical supply chains
Decentralized clinical trials (DCTs) boost efficiency for CGTs and rare disorders
Next-generation sequencing (NGS) and liquid biopsy revolutionize oncology diagnostics
Failed clinical trials and shifting market conditions setback biotech innovation
ESG initiatives climb to the top of CEOs' strategic priorities
Real-world insight (RWI) emerges as a strategic compass point to reimagine commercial strategies
CRISPR technology advances biologics R&D

Table of Contents

Strategic Imperatives
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
Top Transformations Impacting the Growth of the Life Sciences Industry
Key Industry Trends and Challenges
Top 10 Transformations Impacting Growth in the Life Sciences Industry, 2025
Transformation 1: SaaS Evolution Provides Adaptive Intelligence for Laboratories
Transformation 2: CDMOs Augment Competencies in New Modalities, and Digital Transformation Delivers End-to-End Partnerships
Transformation 3: Expanding Direct-to-Consumer (DTC) Genetic Testing Beyond Ancestry Testing to Multi-pathogenic STIs
Transformation 4: Uncertainty About Trade Wars Disrupts Pharmaceutical Supply Chains
Transformation 5: Decentralized Clinical Trials (DCTs) Boosting Efficiency for CGTs and Rare Disorders
Transformation 6: Next-generation Sequencing (NGS) and Liquid Biopsy Revolutionize Oncology Diagnostics
Transformation 7: Failed Clinical Trials and Shifting Market Conditions Setback Biotech Innovation
Transformation 8: ESG Initiatives Climb to the Top of CEOs' Strategic Priorities
Transformation 9: Real-world Insight (RWI) Emerges as a Strategic Compass Point to Reimagine Commercial Strategies
Transformation 10: CRISPR Technology Advances Biologics R&D
Frost & Sullivan Analytics Perspectives
Next Steps
Benefits and Impacts of Growth Opportunities
Next Steps
Legal Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.